(Albany, United States) As per DelveInsight’s assessment, globally, the Metastatic Colorectal Cancer Pipeline constitutes 130+ key companies continuously working towards developing 140+ Metastatic Colorectal Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Metastatic Colorectal Cancer Pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Colorectal Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer Pipeline treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
DelveInsight’s Metastatic Colorectal Cancer Pipeline analysis depicts a robust space with 130+ active players working to develop 140+ pipeline treatment therapies.
The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, and others.
On August 2023, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc announced a study of phase 1 & 2 clinical trials for ZN-c3, Encorafenib, and Cetuximab. The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
On August 2023, Arcus Biosciences Inc. announced a study of phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Regorafenib. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Metastatic Colorectal Cancer Overview
Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ.
For further information, refer to the detailed Metastatic Colorectal Cancer Unmet Needs, click here for Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis
Metastatic Colorectal Cancer Emerging Drugs Profile
Adagrasib (MRTX849): Mirati Therapeutics
QL-1203: Qilu Pharmaceutical
ZN-c3: Zentalis Pharmaceuticals
Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 130+ key companies which are developing the therapies for Metastatic colorectal cancer. The companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.
Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Metastatic Colorectal Cancer Segmentation
Metastatic Colorectal Cancer Drugs and Companies
Cetuximab: Pfizer
CMAB009 plus Irinotecan: Shanghai Zhangjiang Biotechnology Limited Company
Trifluridin/Tipiracil: Servier Deutschland GmbH
Metastatic Colorectal Cancer Therapeutics Assessment
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Some of the Companies in the Metastatic Colorectal Cancer Therapeutics Market include-
Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Dive deep into rich insights for drugs for Metastatic Colorectal Cancer Pipeline, click here @ Metastatic Colorectal Cancer Unmet Needs and Analyst Views
Scope of the Metastatic Colorectal Cancer Pipeline Report
Coverage- Global
Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, and others.
Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Metastatic Colorectal Cancer Merger and acquisitions, Licensing Activities
Table of Content
Introduction
Executive Summary
Metastatic colorectal cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic colorectal cancer Collaboration Deals
Late Stage Products (Phase III)
MRTX849: Mirati Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK-112: Akeso Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SY 5609: Syros Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Metastatic colorectal cancer Key Companies
Metastatic colorectal cancer Key Products
Metastatic colorectal cancer- Unmet Needs
Metastatic colorectal cancer- Market Drivers and Barriers
Metastatic colorectal cancer- Future Perspectives and Conclusion
Metastatic colorectal cancer Analyst Views
Metastatic colorectal cancer Key Companies
Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
